Binge Eating Disorder - Pipeline Review, H2 2016

Published: Oct, 2016 | Pages: 58 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H2 2016, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape.

Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase your risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that eating behavior is out of control and experiencing depression and anxiety. Treatment includes psychotherapy, medications and behavioral weight-loss programs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Binge Eating Disorder - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 1 and 4 respectively for Binge Eating Disorder.

Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Binge Eating Disorder (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Binge Eating Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Binge Eating Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Binge Eating Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Binge Eating Disorder (Central Nervous System)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Binge Eating Disorder (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Binge Eating Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Binge Eating Disorder Overview 6
Therapeutics Development 7
Pipeline Products for Binge Eating Disorder - Overview 7
Binge Eating Disorder - Therapeutics under Development by Companies 8
Binge Eating Disorder - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Binge Eating Disorder - Products under Development by Companies 12
Binge Eating Disorder - Companies Involved in Therapeutics Development 13
Chronos Therapeutics Limited 13
F. Hoffmann-La Roche Ltd. 14
Heptares Therapeutics Limited 15
Highland Therapeutics, Inc. 16
Omeros Corporation 17
Opiant Pharmaceuticals, Inc. 18
Shire Plc 19
Sunovion Pharmaceuticals Inc. 20
Binge Eating Disorder - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 29
CTDP-002 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
dasotraline hydrochloride - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
dextroamphetamine - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
lisdexamfetamine dimesylate - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
naloxone hydrochloride - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
OMS-527 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
RO-5256390 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Binge Eating Disorder - Dormant Projects 45
Binge Eating Disorder - Discontinued Products 46
Binge Eating Disorder - Product Development Milestones 47
Featured News & Press Releases 47
Oct 17, 2016: Shire Announces Update to Vyvanse (lisdexamfetamine dimesylate) U.S. Labeling to Include New Longer-Term Maintenance of Efficacy Data in Adults with Moderate to Severe Binge Eating Disorder 47
Oct 06, 2016: Study Finds New Approach to Block Binge Eating 48
Apr 14, 2016: Shire Submits NDA to FDA for New Formulation of Vyvanse (lisdexamfetamine dimesylate) CII as Chewable Tablets 48
Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline 49
Jul 22, 2015: Vyvanse (lisdexamfetamine dimesylate) Positive Top-Line Results in Maintenance of Efficacy Study in Adults with Moderate to Severe Binge Eating Disorder 50
Jun 13, 2015: PTAB Invalidates Lucerne Biosciences' '813 Patent for the Treatment of Binge Eating Disorder with Lisdexamfetamine Dimesylate 52
May 11, 2015: Shire to Present New Research at American Psychiatric Association Annual Meeting 52
Jan 30, 2015: Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults with Moderate to Severe Binge Eating Disorder 53
Sep 15, 2014: Shire Announces FDA Acceptance for Filing with Priority Review of Supplemental New Drug Application (sNDA) for Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) for Adults with Binge Eating Disorder 54
Nov 05, 2013: Positive Top-line Results Shown for Vyvanse Capsules in Adults with Binge Eating Disorder 54
May 17, 2013: Shire To Present Scientific Data On Vyvanse At 166th APA Annual Meeting 2013 55
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables

Number of Products under Development for Binge Eating Disorder, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Late Stage Development, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 10
Comparative Analysis by Early Stage Development, H2 2016 11
Products under Development by Companies, H2 2016 12
Binge Eating Disorder - Pipeline by Chronos Therapeutics Limited, H2 2016 13
Binge Eating Disorder - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 14
Binge Eating Disorder - Pipeline by Heptares Therapeutics Limited, H2 2016 15
Binge Eating Disorder - Pipeline by Highland Therapeutics, Inc., H2 2016 16
Binge Eating Disorder - Pipeline by Omeros Corporation, H2 2016 17
Binge Eating Disorder - Pipeline by Opiant Pharmaceuticals, Inc., H2 2016 18
Binge Eating Disorder - Pipeline by Shire Plc, H2 2016 19
Binge Eating Disorder - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 20
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Stage and Target, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 28
Binge Eating Disorder - Dormant Projects, H2 2016 45
Binge Eating Disorder - Discontinued Products, H2 2016 46